Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of …
$4.33+5.87%
报价 2026-11-06
市值
$1.41B
EV
$687.4M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -38.0%
$3.51$6.98
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| TSHATaysha Gene Therapies, Inc. | $1.41B | +5.9% | -66.1% | 94% | – | – | – | |
| DNTHDianthus Therapeutics, Inc. | $4.81B | +3.6% | -45.5% | 94.3% | – | – | – | |
| ELVNEnliven Therapeutics, Inc. | $3.62B | +10.4% | – | 0% | – | – | – | |
| XNCRXencor, Inc. | $2.66B | +5.0% | +15.5% | 93.9% | – | – | – | |
| ANABAnaptysBio, Inc. | $1.39B | +1.9% | -48.8% | 99% | – | 27.8x | 68.4x | |
| NKTRNektar Therapeutics | $1.07B | +3.1% | -5.3% | 99.4% | – | – | – | |
| IMTXImmatics N.V. | $951.7M | +2.9% | – | 100% | – | – | – | |
| SANASana Biotechnology, Inc. | $709.5M | +1.3% | – | 0% | – | – | – | |
| OCSOculis Holding AG | $462.4M | +9.7% | – | -2,889.4% | – | – | – | |
| 同行中位数 | – | – | -25.4% | 94.1% | – | 27.8x | 68.4x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。